Glaukos Corporation (GKOS)

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Ch...

Glaukos (GKOS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.70 per share a year ago.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...